GlassScriptPhysician profile
Lindsey Smith
NPI 1588031967
$828.82
in general payments reported to CMS, 2019-2025
14 companies · $80.90 in 2025
The $80.90 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.36 · 2022: $382 · 2023: $158 · 2024: $130 · 2025: $80.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $340.01 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $134.65 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Currax Pharmaceuticals LLC | $63.19 | 2023-2025 | Contrave |
| Evoke Pharma, INC. | $63.19 | 2021-2022 | |
| Janssen Biotech, INC. | $53.39 | 2022-2023 | Stelara |
| Ipsen Biopharmaceuticals, INC | $40.22 | 2025 | Iqirvo |
| Abbvie INC. | $18.72 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.80 | 2024 | Voquezna |
| Pfizer INC. | $17.72 | 2023 | |
| Novo Nordisk INC | $16.35 | 2024 | Rybelsus, Ozempic |
| Intra-Sana Laboratories | $14.94 | 2021 | |
| Medline Industries LP | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.